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Photodynamic therapy using 5-aminolevulinic acid (ALA)-induced protoporphyrin IX (PpIX) may be applied to the treatment
of neoplasms in a variety of organs. In order to enhance existing regimens of photodynamic therapy, we investigated the
effects of adding differentiation therapy to photodynamic therapy in human prostate cancer cells in vitro. The objective of
differentiation therapy per se is to reverse the lack of differentiation in cancer cells using pharmacological agents. The
motivation for this study was to exploit the differentiation-dependent expression of some heme enzymes to enhance tumour
cell toxicity of ALA-photodynamic therapy. A short course of differentiation therapy was applied to increase PpIX formation
during subsequent ALA exposure. Using the synthetic androgen R1881, isomers of retinoic acid, and analogues of vitamin D
for 3 to 4 days, exogenous ALA-dependent PpIX formation in LNCaP cells was increased, along with markers for growth
arrest and for differentiation. As a consequence of higher PpIX levels, cytotoxic effects of visible light exposure were also
enhanced. Short-term differentiation therapy increased not only the overall PpIX production but also reduced that fraction of
cells that contained low PpIX levels as demonstrated by ﬂow cytometry and ﬂuorescence microscopy. This study suggests that
it will be feasible to develop protocols combining short-term differentiation therapy with photodynamic therapy for enhanced
photosensitisation.
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Photodynamic therapy (PDT), the administration of an exogenous
photosensitizer plus light, is becoming increasingly recognised as a
viable alternative to other cancer therapies (Hasan et al, 2000).
Recently, a newer approach to PDT has attracted much interest,
namely, the application of a pro-drug (5-aminolevulinic acid,
ALA) that is converted in situ into a photosensitizing compound
(protoporphyrin IX, PpIX) (Peng et al, 1997). While ALA-
mediated PDT has shown some promise in pilot studies of certain
malignancies to date, including cancers of the skin (Svanberg et al,
1994; Fijan et al, 1995; Peng et al, 1997), the number of treatment
failures remains unacceptable. While a variety of mechanisms may
lead to these treatment failures, all failures by deﬁnition involve a
subpopulation of cancer cells that manage to escape cell death. One
promising and relatively unexplored approach to improving the
efﬁcacy of cell-killing is to alter biological responses of the target
cancer cells, in a manner that enhances susceptibility to ALA-
mediated PDT. One example of such an approach is the use of
short-term differentiation therapy.
Differentiation therapy (DT) makes use of the fact that cancer
cells often do not progress through the normal processes of growth
arrest, differentiation, and scheduled apoptosis, and thus circum-
vent cell death (Andreeff et al, 2000). To counteract these
abnormalities, pharmacological agents are applied to redirect aber-
rant pathways, so that cancer cells mature and eventually undergo
normal apoptosis. A familiar clinical DT paradigm is the use of
retinoic acid, administered over several months in patients with
promyelocytic leukemia (APML) (Fenaux et al, 2001). DT causes
abnormal promyelocytes to differentiate, becoming segmented
granulocytes with a limited lifetime (Glasser et al, 1994). Our
approach to DT differs from the traditional deﬁnition of DT in
two respects: (1) it exploits the fact that a photosensitising
porphyrin intermediate, PpIX, can accumulate to high levels
preferentially in differentiated cells (see below); (2) the differentia-
tion-modulating agent is administered over a relatively short
period of time (days) to prepare the cells for a second therapeutic
modality, namely exposure to ALA and light.
The approach described here arose out of an exploration of the
capacity of cells to synthesise PpIX (the photosensitiser) from ALA
(the pro-drug), and is based upon the ﬁnding that cellular differ-
entiation increases the ability of a variety of cells to synthesise PpIX
from exogenous ALA (Ortel et al, 1998). For example, induction of
differentiation in skin keratinocytes (by increasing calcium concen-
trations in the culture medium) leads to an accumulation in PpIX,
involving upregulation of the heme-synthetic enzyme coproporphyr-
inogen oxidase, and results in signiﬁcantly increased
photosensitisation (Ortel et al, 1998). Here, we evaluate a similar
approach, but now using DT and ALA-PDT for human prostate
cancer cells. Previous work by our group used the LNCaP cell line
in PDT studies (Momma et al, 1998; Hamblin et al, 1999) and
showed that ALA-induced PpIX formation can be manipulated
by androgenic hormones (Momma et al, 1997). Our current work
extends that concept by showing that other agents can also alter
PpIX levels when used in a short-term course for DT. Furthermore,
we demonstrate that DT enhances lethal photosensitisation. The
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www.bjcancer.comdata suggest that combination regimens consisting of DT using
vitamin D or its analogues, followed by cell-killing with ALA-
PDT, may represent a useful therapeutic approach to the manage-
ment of prostate cancer.
MATERIALS AND METHODS
Cell culture conditions
Human LNCaP cells were obtained from American Type Culture
Collection (Rockville, MD, USA) and grown in RPMI 1640
(Mediatech, Inc., Herndon, VA, USA) supplemented with anti-
biotics, 10 mm HEPES, and 10% foetal calf serum (FCS, Gibco,
Invitrogen Corporation, Carlsbad, CA, USA) at 378C in a humidi-
ﬁed atmosphere of 5% CO2. All experiments were done using
duplicate samples and at least three different times.
Chemicals
ALA was obtained from Sigma (St. Louis, MO, USA), R1881
(methyltrienolone) was from PerkinElmer Life Sciences (Boston,
MA, USA). Vitamin D (in the form of calcitriol), and its analogues
RO-26-2198 and RO-25-9022 were synthesised and previously
described by Dr Milan Uskokovic (Hofmann LaRoche, Nutley,
NJ, USA), who provided them as generous gifts. All-trans-,
9-cis-, and 13-cis-retinoic acid were from Sigma.
Differentiation therapy
For DT, cells were plated at a density of 7.5 to 15610
4 cells per
35 mm petri dish. After 24 h the medium was replaced with
medium supplemented with delipidised 10% foetal calf serum
(Cocalico Biologicals, Inc., Reamstown, PA, USA). The differentiat-
ing agents were diluted into pre-warmed medium and immediately
added to the cells. Controls included medium with delipidised FCS
and delipidised FCS plus vehicle. All agents were used as a single
pulse dose of 72 h duration.
DNA synthesis assay
Cells (3–4610
5 per 35 mm dish) were incubated with 1 mCi ml
71
[methyl-
3H]thymidine (20.0 Ci mmol
71 from Dupont/NEN,
Wilmington, DE, USA) in 0.5 ml media. After 4 h DNA was
isolated by acid precipitation and tritium quantiﬁed as described
previously (Alge et al, 2001).
Western blotting
Whole cell lysates were obtained by dissolving cells in gel loading
buffer, separated on 10 or 12% polyacrylamide gels and transferred
onto a Immobilon-P membrane (Millipore, Bedford, MA, USA). E-
cadherin and p27/kip-1 were detected using monoclonal mouse
antibodies directed against human E-cadherin or human p27
(Santa Cruz Biotechnology, Santa Cruz, CA, USA). A horseradish
peroxidase-coupled goat antibody against mouse immunoglobulin
(Bio-Rad Laboratories, Hercules, CA, USA) was used for chem-
iluminescence detection.
PpIX production and quantiﬁcation
Cells in 35 mm dishes were incubated in duplicate in 1 ml medium
containing 0.1 to 1.0 mM ALA. All manipulations of ALA-treated
cells were performed under reduced light conditions. After 4 h,
samples were used for PpIX quantiﬁcation as previously described
(Ortel et al, 1998). In brief, cells were solubilised in 1% SDS in
0.1 N NaOH and submitted to quantitative spectroﬂuorometry
(excitation 400 nm, emission 580–720 nm, peak 630 nm).
Fluorescence analysis in living cells
Fluorescence of living cells was analysed by ﬂuorescence micro-
scopy and by ﬂow cytometry. Cells were plated and treated
identically to the conditions used to quantify PpIX. For ﬂuores-
cence microscopy, cells were grown on glass cover slips. A Leica
confocal laser scanning microscope (Leica Mikroskopie und
System GmbH, Wetzlar, Germany) was used as described in
detail earlier (Pogue et al, 2001). In brief, the ﬂuorescence signal
was separated into a green (525–550 nm) and a red (4590 nm)
portion. Fluorescence images were displayed in green and red
false colour and electronically overlaid. Fluorescence of individual
cells was quantiﬁed using ﬂow cytometry (Facscalibur, Beckton
Dickinson). ALA-treated cells were incubated for 30 s in tryp-
sin/EDTA (0.25/0.1%) and resuspended after addition of
complete medium. Cell suspensions were put on ice and analysed
without delay. Using excitation at 488 nm, red ﬂuorescence emis-
sion of 10000 cells was recorded through a 670 nm longpass
ﬁlter.
Photosensitisation
Cells (3–5610
5 per 35 mm dish) were incubated with 0.3 mM
ALA for 4 h and then exposed from below to the expanded homo-
genous beam of 514 nm Argon laser radiation (Coherent, Inc.,
Santa Clara, CA, USA) at a dose rate of 0.06 to 0.075 Wcm
72 as
measured by a Coherent Lasermate power meter.
MTT survival assay
Quantiﬁcation of cellular dehydrogenase activity provides a sensi-
tive way of assessing survival after PDT and has been shown to
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Figure 1 Growth arrest and differentiation in LNCaP cells. Treatment
with 10
77 M R1881 suppressed the growth of LNCaP cells as documented
by (A) reduced incorporation of tritiated thymidine. Western blotting
(B,C) demonstrated (B) upregulation of the cell cycle inhibitor p27/Kip-
1 and the differentiation marker E-cadherin (C) after R1881 treatment.
(D) Protein staining with Coomassie blue served as loading control.
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as colony formation (Iinuma et al, 1994). The MTT assay was
performed at 24 h after light exposure as described in detail earlier
(Ortel et al, 1998).
Clonogenic assay
After ALA-PDT as described above, LNCaP cells were detached
using trypsin/EDTA and resuspended in complete medium. Diluted
suspensions (range 1:5 to 1:1375) were plated on 100 mm dishes
and incubated for 13 days. Cells were ﬁxed with 0.2% buffered
formalin in methanol and stained with 0.1% aqueous crystal violet.
Colonies of more than 50 cells were counted under a dissecting
microscope.
Statistical analysis
The t-test for comparison of means or the paired t-test was used
for statistical analysis. P-values less than 0.05 were considered
statistically signiﬁcant.
RESULTS
Androgen treatment of LNCaP cells arrests growth and
induces differentiation
Exposure of LNCaP cells to 10
77 M R1881 resulted in reduced
DNA synthesis by 48–72 h (
3H-thymidine incorporation, Figure
1A). Simultaneously, p27/Kip 1, an inhibitor of cyclin-dependent
kinases whose upregulation correlates with growth-arrest, was
increased at the protein level up to 3.4 times as shown by Western
blotting (Figure 1B). Furthermore, R1881 treatment resulted in a
more than two-fold rise in E-cadherin protein expression (Figure
1C), a generally-accepted indicator of differentiation in LNCaP
cells (Campbell et al, 1999).
Androgen treatment of LNCaP cells increases ALA-induced
PpIX production
When LNCaP cells were pretreated with 10
77 M R1881 for 72 h,
subsequent exposure to 0.3 mM ALA induced 28.6+27.2-fold
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Figure 2 Increased ALA-induced PpIX production in cells treated with R1881. Pretreatment variables were (A) R1881 concentration (exposure for 72 h)
and (B) R1881 incubation time (at 10
77 M). (C) At all ALA concentrations, R1881(10
77 M)-pretreated cells (~) accumulated higher PpIX amounts than
control cells (O). (D) When incubating differentiated cells with 0.2 mM ALA (~) and undifferentiated cells with 0.6 mM ALA (O), respectively, there was a
linear increase in PpIX content in both sets of cells. Experiments show mean+s.d. values of duplicate samples.
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(11), 1321–1327higher PpIX accumulation in androgen-pretreated cells than in
proliferating control cells (13 experiments, two dishes/experiment).
This effect depended on R1881 dose and exposure time (Figure
2A,B). Androgen-pretreated cells produced at least twice the
amount of PpIX as control cells at all concentrations up to
1m M (Figure 2C). Androgen-differentiated and control cells were
also treated with different concentrations of ALA to reach similar
PpIX formation. In this setting, both samples showed very similar
and linear increase of PpIX content (Figure 2D).
Androgen pretreatment increases ALA-induced
phototoxicity
R1881-treated (10
77 M, 72 h) and control LNCaP cells were incu-
bated with 0.3 mM ALA for 4 h and then exposed to 514 nm
radiation. R1881-treated cells were killed at much lower ﬂuences
than undifferentiated cells (Figure 3A). The increase in phototox-
icity was shown to be statistically signiﬁcant using MTT conver-
sion (Figure 3A). The light dose requirements were calculated
from the slopes of the survival curves. There was a 58+28-fold
dose ratio of the irradiation required to reduce survival to 50%
in differentiated vs undifferentiated cells. The evaluation of colony
formation as endpoint of phototoxicity also showed a highly
signiﬁcant increase in phototoxicity in R1881-treated cells (Figure
3B).
Androgen pretreatment does not inherently increase
phototoxic efﬁciency
In order to compare phototoxicity at equal cellular PpIX concen-
trations, undifferentiated cells were treated with 0.6 mM ALA
while R1881-treated cells received 0.2 mM ALA. Both sets of cells
produced similar amounts of PpIX (Figure 2C,D). Using these
conditions, we compared the phototoxic efﬁcacy (survival as a
function of the combined PpIX concentration and irradiation
dose). There was a shift of the survival curve of the R1881-treated
cells indicating increased resistance to PDT as compared to undif-
ferentiated cells (Figure 3C). This difference was small but
statistically signiﬁcant (P50.05).
Androgen treatment increases the fraction of cells with
high PpIX concentration
R1881-treated cells not only showed higher average concentrations
of PpIX than control cells (Figure 2), but also contained a larger
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Figure 3 Photosensitisation of DT-exposed cells. LNCaP cells pretreated for 72 h with 10
77 M R1881 (~) and control cells (O) were incubated for 4 h
with 0.3 mm ALA and irradiated. PpIX-mediated phototoxicity was signiﬁcantly enhanced in androgen-pretreated cells (~) using (A) MTT conversion and
(B) colony formation as endpoints. Differentiated (~) and control cells (O) containing similar amounts of PpIX (C) showed a small decrease in photo-
sensitivity in the differentiated cells. (D) Pretreatment with 10
77 M Ro-26-2198 for 96 h before photosensitisation resulted in increased cytotoxicity in
Ro-26-2198-treated cells (~) as compared to control cells (O), as assessed by MTT conversion. All data points are mean+s.d. values of duplicate samples.
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PpIX concentrations. Figure 4 shows transmission and ﬂuorescence
microscopy, and ﬂow cytometry histograms to illustrate this point.
Vehicle-treated controls incubated with ALA (Figure 4B) showed a
large fraction of cells that displayed the same low red ﬂuorescence
intensities as untreated cells without ALA incubation (Figure 4A).
In R1881-pretreated, ALA-treated samples (Figure 4C) the vast
majority of cells showed strong ﬂuorescence. More than 80% of
the androgen-pretreated cells exhibited strong cellular red ﬂuores-
cence, while the majority of vehicle-treated control cells yielded
background ﬂuorescence levels.
Differentiation therapy with vitamin D and its derivatives
increases ALA-induced PpIX and ALA-PDT
Although R1881 is a useful agent in vitro, it is unlikely that andro-
gens will be used for prostate cancer in a clinical setting. Therefore
we investigated the effect of several differentiation-inducing agents
that may be useful in vivo. We tested vitamin D and its synthetic
analogues Ro-25-9022 and Ro-26-2198, and all-trans-, 9-cis-, and
13-cis-retinoic acid (Figure 5). All vitamin D compounds signiﬁ-
cantly increased ALA–PpIX accumulation in LNCaP cells.
Vitamin D was active at 10 and 100 nM, while the derivatives
showed similar efﬁcacy at 10-fold lower concentrations (Figure
5). Retinoid treatment even at 10 mM induced only moderate
ALA–PpIX increases that did not reach statistical signiﬁcance.
Finally, the vitamin D analogue Ro-26-2198 was examined for
its effect on ALA-dependent photosensitisation. Pretreatment of
LNCaP cells with Ro-26-2198 resulted in signiﬁcantly increased
phototoxicity (Figure 3D).
DISCUSSION
This report demonstrates that a combination of differentiation
therapy (DT) and PDT may be useful for enhancing cytotoxic
effects on cancer cells. ALA-induced protoporphyrin IX (PpIX)
production was markedly increased in LNCaP cells after treatment
with differentiating agents such as R1881, and analogues of vitamin
D, resulting in signiﬁcantly enhanced phototoxicity in the differen-
tiated cells. This was in contrast to many reports showing higher
PpIX levels in more rapidly proliferating cells but conﬁrmed our
own ﬁndings in an earlier report (Ortel et al, 1998, and references
therein). While the photodynamic sensitivity was slightly decreased
in differentiated LNCaP cells as compared to controls (see below),
enhanced PpIX production far outweighed the small reduction of
PDT efﬁcacy in DT-pretreated cells. Perhaps our most important
ﬁnding, from a therapeutic standpoint, is the demonstration that
increased PpIX levels result not from very large increases in a
few cells, but rather from a more-or-less uniform increase of PpIX
in many cells across the board. Thus, our ﬂow-cytometry data
(Figure 4) reveals that differentiating agents tend to shift a majority
of cells above the threshold for cell-killing. This population effect
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Figure 4 PpIX ﬂuorescence in living cells. LNCaP cells were pretreated with vehicle (A,B) or with 10
77 M R1881 for 72 h (C). Microscopy. Transmission
and ﬂuorescence images of untreated LNCaP cells (A) and cells exposed to 0.3 mm ALA (B,C) without (B) or with (C) pretreatment with R1881. Flow
cytometry. A large fraction of 0.3 mM ALA-treated control cells (B) did not show more intense ﬂuorescence than cells (A) that were not exposed to ALA.
Pretreatment with R1881 (10
77 M for 72 h) (C) resulted in strongly increased ﬂuorescence in the vast majority of cells.
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50% cytotoxicity in undifferentiated cells, are more than 50 times
higher than those required in differentiated (R1881-pretreated)
cells.
Normal regulation of proliferation, differentiation, and apopto-
sis is lost in cancer cells (Andreeff et al, 2000). Because these three
aspects are interconnected (i.e., arrest of the cell-cycle is a pre-
requisite for differentiation, and differentiation ultimately results
in cell death in many systems (Sorrentino et al, 1990; Umek et
al, 1991; Morioka et al, 1998; Gandarillas et al, 1999; Zermati et
al, 2000), DT exploits these associations and restores pathways that
have been apparently lost during carcinogenesis. The typical clinical
paradigm of DT, epitomized by all-trans-retinoic acid (ATRA)
treatment of APML, requires months of pharmacological therapy.
ATRA induces maturation of the cancer cells along the granulocy-
tic lineage (Breitman et al, 1981) and eventual apoptosis. ATRA is
efﬁcient in new and relapsed APML, but may induce resistance to
further ATRA therapy (Dore et al, 1994). We approach DT from a
different perspective. In our combined regimen, DT does not aim
at persistent cellular differentiation, growth arrest, and apoptosis
but rather exploits short-term cellular alterations in response to
androgens, retinoids, or vitamin D. While a short course of DT
may not have any long-term therapeutic effect on its own,
unwanted long-term side effects (e.g. vitamin D effects on calcium
metabolism) may be largely prevented by the brevity of exposure to
the differentiating agent.
The success of our approach, using cellular differentiation to
modulate ALA-PDT, depends upon the availability of suitable
differentiation-modulating agents that work in the tumor of inter-
est. We began these studies using R1881, a well-established
modulator of androgen-responsive LNCaP cells (Esquenet et al,
1997). R1881 induced growth arrest and differentiation in LNCaP
cells, as demonstrated by reduced DNA synthesis and expression of
the molecular markers p27/Kip 1 and E-cadherin (Figure 1).
Complete terminal differentiation, however, may not be a prerequi-
site for enhanced ALA-PDT. Perhaps only a few neoplastic cell
types will undergo a complete differentiation program, but as long
as PpIX formation is enhanced to therapeutic levels by the DT,
then the objective of the combined regimen will have been
achieved. By the same token, differentiation may not enhance PpIX
formation in all cells or tumour types. This was demonstrated in
the promyelocytic leukemia cell line HL-60, in which DMSO-
induced differentiation did not result in increased PpIX production
(Li et al, 1999). Similarly, larger amounts of PpIX were accumu-
lated in lectin-stimulated lymphocytes, than in non-stimulated,
non-dividing cells (Rittenhouse-Diakun et al, 1995). These observa-
tions illustrate that not all cell-types may be amenable to DT as a
way to augment the efﬁcacy of ALA-PDT, and that the cell type
along with the cell’s baseline heme-synthetic capacity, may deter-
mine PpIX accumulation after induction of differentiation.
An association of differentiation and increased ALA–PpIX
formation was ﬁrst described in an erythroleukemia cell line, in
which increased heme synthesis is an integral part of the erythro-
cyte-speciﬁc differentiation program (Malik et al, 1989). In
differentiated primary mouse keratinocytes several factors were
shown to contribute to elevated cellular PpIX levels, including
increased ALA uptake and enhanced PpIX production (Ortel et
al, 1998). Here in LNCaP cells, as in primary keratinocytes (Ortel
et al, 1998), the large increases of PpIX in differentiated cells
resulted in strongly increased phototoxicity compared with non-
differentiated cells exposed to the same ALA concentration (Figure
3).
Several potential caveats to our conclusions should be
mentioned. First, to evaluate the inherent metabolic sensitivity of
proliferative vs differentiated cells to ALA-PDT injury, we irra-
diated undifferentiated and differentiated cells that contained
similar levels of PpIX (to determine photodynamic efﬁciency),
and found that DT actually decreased the inherent cellular sensitiv-
ity to PDT. While the difference was statistically signiﬁcant, it was
much smaller than the selective enhancement of PpIX production
in differentiated vs proliferating cells incubated at the same ALA
concentration. Secondly, androgens are unlikely candidates for
clinical use in prostate cancer, because of the risk of encouraging
growth in certain cell clones. Therefore, it is encouraging that
the activity of vitamin D and its synthetic analogues Ro-25-9022
and Ro-26-2198 bears promise for use in in vivo protocols. The
high efﬁciency of the vitamin D analogues at low concentration,
and the short course of DT required, make potential effects of
these agents on calcium homeostasis a relatively minor concern
(Shiohara et al, 2001). It remains to be determined, how speciﬁc
short-term DT regimens will affect tumour biology and other
factors in ALA-dependent PDT in vivo. These factors include local
ALA concentration, and homogeneity of PpIX production, both
important in the assessment of clinical applicability in vivo.
However, the capability of DT to strongly enhance the efﬁcacy of
PpIX formation at all ALA concentrations studied may help to
make future clinical protocols more efﬁcient, less toxic, or both.
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Figure 5 Increased PpIX accumulation after treatment with differentiat-
ing agents. LNCaP cells were pretreated with vehicle, retinoids, vitamin D,
or vitamin D analogues for 96 h. R1881 (10
77 M) served as positive con-
trol. Vitamin D and the analogues Ro-25-9022 and Ro-26-2198 strongly
enhanced PpIX formation. Even 1000-fold higher doses of the retinoids
showed only moderate or no increase in ALA-dependent PpIX formation.
Values represent mean+s.d. of 3–8 samples.
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